NeuroPace is the developer and manufacturer of the RNS System, a proven treatment option for adults who have disabling seizures that are not controlled by medication. The RNS System is the only medical device that is smart enough to respond to what’s happening in the brain to stop seizures at their source.
Safety Information
The RNS® System is an adjunctive therapy in reducing the frequency of seizures in individuals 18 years of age or older with partial onset seizures who have undergone diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to two or more antiepileptic medications, and currently have frequent and disabling seizures.
Please refer to the product labeling for a detailed disclosure of specific indications, contraindications, warnings, precautions and adverse events. Rx only.
Safety Information
The RNS® System is an adjunctive therapy in reducing the frequency of seizures in individuals 18 years of age or older with partial onset seizures who have undergone diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to two or more antiepileptic medications, and currently have frequent and disabling seizures.
Please refer to the product labeling for a detailed disclosure of specific indications, contraindications, warnings, precautions and adverse events. Rx only.
Location: United States, California, Mountain View
Employees: 51-200
Phone: (866) 726-3876
Total raised: $150.3M
Founded date: 1999
Investors 6
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| 06.07.2021 | New Enterp... | nea.com |
| - | UCLA Ventu... | ventures.u... |
| - | KCK Medtec... | kckmedtech... |
| - | CRG | crglp.com |
| - | OrbiMed | orbimed.co... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 03.07.2021 | Grant | $9.3M | - |
| 31.08.2020 | - | $67M | - |
| 24.10.2017 | - | $74M | - |
Mentions in press and media 25
| Date | Title | Description |
| 20.01.2026 | Juniper Biomedical Wins Phase 3 NIH SPARC Neuromod Prize And Adds Frank Fischer to Board | Juniper Biomedical has won Phase 3 of the NIH SPARC Neuromod Prize, earning a $1.6 million cash award that the company said will support ongoing product development and clinical trials for its lead therapy targeting mixed urinary incontinen... |
| 27.10.2025 | Couples Impacted by Epilepsy Come Together for Groundbreaking Relationship Retreat in Princeton, NJ | Couples impacted by epilepsy gathered at The Peacock Inn in Princeton, NJ, for Navigating Us: Connecting Through the Epilepsy Journey, a relationship-centered retreat hosted by Epilepsy Services of New Jersey. The two-day event offered guid... |
| 05.03.2024 | NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million | - |
| 12.10.2022 | NeuroPace announces first patient implant in trial of neuromod treatment for epilepsy | The NeuroPace RNS system (Image from NeuroPace) NeuroPace (Nasdaq:NPCE) announced that the first patient received their implant in the Nautilus clinical study of its RNS system. The company’s Nautilus study evaluates the safety and efficacy... |
| 12.01.2022 | NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Revenue | MOUNTAIN VIEW, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, today announced its preliminary, unaudit... |
| 12.01.2022 | NeuroPace : Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Revenue - Form 8-K | NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2021 Revenue Mountain View, Calif. - January 11, 2022 - NeuroPace, Inc. (Nasdaq: NPCE), a commercial-stage medical device company focused on transforming the lives of pe... |
| 22.12.2020 | Epileptic Seizures Aren’t Entirely Random. Discovery May Lead To Seizure Forecasting System | |
| 04.09.2020 | StartUPDATES: New developments from healthcare startups | Self-insured employers, including several Fortune 500 companies, leverage Carrum Health’s technology-powered COE platform to avoid variation in the cost and quality of surgery and to deliver a superior patient experience. The platform enabl... |
| 31.08.2020 | NeuroPace : Raises $67 Million Financing to Support Commercial Expansion of the RNS® System for Refractory Epilepsy | NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced it has raised $67 million in a funding round led by Accelmed Partners with participation from an unnamed strategic investor, Revelation Partners, Soleus Cap... |
| 31.08.2020 | NeuroPace Grabs $67M Funding | MOUNTAIN VIEW, CA, NeuroPace announced that it had raised $67 million in a funding round led by Accelmed Partners. >> Click here for more funding data on NeuroPace >> To export NeuroPace funding data to PDF and Excel, click ... |
Show more